ELVN
Enliven Therapeutics, Inc.
There isn't enough reported data to score ELVN yet.
ELVN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
ELVN's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
ELVN PE Valuation
ELVN has no meaningful PE right now: it lost money over the past year.
ELVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect ELVN's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
ELVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.68 | +$0.16 |
| Q2 2026 | -$1.64 | +$0.36 |
| Q1 2026 | -$1.64 | +$0.28 |
| Q4 2025 | -$1.83 | +$0.06 |
| Q3 2025 | -$1.84 | -$0.12 |
| Q2 2025 | -$2.00 | -$0.25 |
| Q1 2025 | -$1.92 | -$0.17 |
| Q4 2024 | -$1.89 | +$0.12 |
ELVN is still losing money, but far less than before: $1.68 per share over the past year, against $9.48 at its worst in late 2021.
ELVN Quarterly Revenue
ELVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12.6M | +$629K |
| Q2 2026 | -$18.6M | -$1.4M |
| Q1 2026 | -$19.3M | +$4.9M |
| Q4 2025 | -$15.8M | +$1.4M |
| Q3 2025 | -$13.3M | -$1.1M |
| Q2 2025 | -$17.2M | +$3.2M |
| Q1 2025 | -$24.1M | -$766K |
| Q4 2024 | -$17.2M | -$4.7M |
ELVN has burned cash in almost every quarter: −$66M over the past year, against −$72M the year before.
ELVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +11.8M shares |
| 1 year | +26% | +15.9M shares |
| 3 years | +90% | +37M shares |
| 5 years | +1153% | +71.8M shares |
| Available history | +8829% | +77.1M shares |
ELVN has 78M diluted shares, up 26% from a year ago.
ELVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -1.9x | Net Cash |
| Q2 2023 | -2.2x | Net Cash |
| Q1 2023 | -4.4x | Net Cash |
| Q4 2022 | -65.8x | Net Cash |
ELVN has more cash than debt.
ELVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.6 | Neutral |
| Stochastic | 41.1 | Neutral |
ELVN's weekly RSI is 53 (neutral) and its Stochastic is 41 (neutral).
ELVN PE vs Healthcare Sector
| Metric | ELVN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ELVN has no meaningful PE right now: it lost money over the past year.
ELVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.2 | 9.3% above |
| 20 week MA | $50.8 | 4.8% below |
| 50 week MA | $40.0 | 21% above |
| 100 week MA | $30.3 | 60% above |
| 200 week MA | $24.8 | 95% above |
ELVN's trend is mixed: it's above four of its five weekly moving averages, and 95% above its 200-week average.
ELVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.0 | $88.1 | +38% |
| 2021 | $88.1 | $9.96 | -89% |
| 2022 | $9.96 | $16.9 | +70% |
| 2023 | $16.9 | $13.8 | -18% |
| 2024 | $13.8 | $22.4 | +62% |
| 2025 | $22.4 | $16.3 | -27% |
| 2026 YTD | $16.3 | $48.3 | +196% |
ELVN is up 196% so far in 2026, after finishing lower in three of the previous six years.